DACLAHEP (Daklatasvir)

DACLAHEP (Daklatasvir) is a modern antiviral drug that helps fight hepatitis C genotypes 1, 2, 3 and 4 in combination with other drugs. It blocks the viral protein NS5A, and prevents infected cells from spreading throughout the body. The effectiveness of DACLAHEP (Daclatasvir) is based on creating a barrier in viral cells and preventing them from multiplying and entering the bloodstream. Thanks to this, with constant intake, it is possible to achieve persistent virological immunity.

The active active ingredient is daclatasvir. To achieve the maximum effect, it is recommended to use it in combination with other inhibitors; today the combination of daclatasvir and sophosbuvir is widespread, and a positive effect has also been proven after their combined administration.

Daclatasvir is a highly specific agent of direct action against the hepatitis C virus and does not have pronounced activity against other RNA and DNA viruses, including HIV . Daclatasvir is an inhibitor of non-structural protein 5A (NS5A), a multifunctional protein essential for replication of the hepatitis C virus, and thus inhibits two stages of the viral life cycle – viral RNA replication and virion assembly. Based on in vitro data , and computer simulation data showed that daclatasvir interacts with the N-terminus within domain 1 of the protein, which can cause structural distortions that prevent the implementation of the function of the NS5A protein. It was found that daclatasvir is a potent pangenotypic inhibitor of the hepatitis C virus replication complex of genotypes 1a, lb, 2a, 3a, 4a, 5a, and 6a with effective concentration values ​​(50% reduction, EC 50 ) from picomolar to low nanomolar.